The drug lowered the genetic instructions in the liver for making the bad cholesterol protein, but didn’t change the instructions for clearing it from the blood.
Scientific Claim
Atorvastatin treatment for 21 days in miniature pigs fed a high-fat, high-cholesterol diet reduces hepatic apoB mRNA abundance by 13% (P=.003), but does not alter hepatic or intestinal LDL receptor mRNA abundance.
Original Statement
“Hepatic apoB mRNA abundance quantitated by RNase protection assay was decreased by 13% in the atorvastatin-treated animals (P=.003). Hepatic and intestinal LDL receptor mRNA abundances were not affected.”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design cannot support claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The abstract reports mRNA changes as observed data with p-values. No causal language is used, and the phrasing matches the data.
More Accurate Statement
“Atorvastatin treatment for 21 days in miniature pigs fed a high-fat, high-cholesterol diet was associated with a 13% reduction in hepatic apoB mRNA abundance (P=.003), with no change in hepatic or intestinal LDL receptor mRNA abundance.”
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Randomized Controlled TrialLevel 1bIn EvidenceThat atorvastatin directly causes a reduction in hepatic apoB mRNA levels in pigs.
That atorvastatin directly causes a reduction in hepatic apoB mRNA levels in pigs.
What This Would Prove
That atorvastatin directly causes a reduction in hepatic apoB mRNA levels in pigs.
Ideal Study Design
A double-blind, placebo-controlled RCT in 20+ miniature pigs, randomized to 3 mg/kg/day atorvastatin or placebo for 21 days, with hepatic apoB mRNA quantified by RNase protection assay as the primary endpoint, and liver biopsies standardized for timing and location.
Limitation: Cannot prove the reduction is the direct cause of decreased apoB secretion without functional validation.
In Vitro StudyLevel 5Whether atorvastatin directly suppresses apoB gene expression in liver cells independent of systemic effects.
Whether atorvastatin directly suppresses apoB gene expression in liver cells independent of systemic effects.
What This Would Prove
Whether atorvastatin directly suppresses apoB gene expression in liver cells independent of systemic effects.
Ideal Study Design
Primary hepatocytes from miniature pigs treated with 0–10 µM atorvastatin for 24–72 hours, measuring apoB mRNA levels via qPCR and protein synthesis via metabolic labeling, with cholesterol supplementation to control for lipid-mediated effects.
Limitation: Cannot replicate whole-body physiology, including lipoprotein kinetics or tissue interactions.
Evidence from Studies
Supporting (1)
Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.
The study gave pigs a cholesterol-lowering drug called atorvastatin for 21 days and found it lowered a specific liver protein message (apoB mRNA) by 13%, just like the claim said — and it didn’t change other related messages in the liver or intestine.